Validation of anti-aging drugs by treating age-related diseases.

Validation of anti-aging drugs by treating age-related diseases.
复制标题

DOI:
10.18632/aging.100034
复制
发表时间:
2009-03-28
期刊:
Aging
影响因子:
--
通讯作者:
Blagosklonny MV
Blagosklonny MV
中科院分区:
其他
文献类型:
--
作者:
Blagosklonny MV

文献摘要

参考文献

被引文献

相似文献

人类死于与年龄相关的疾病,这是衰老过程的致命表现。 为了延长寿命,抗衰老药物必须延缓与年龄相关的疾病。所有与年龄相关的疾病都是衰老的最佳生物标志物。一旦一种药物用于治疗任何一种慢性疾病,就可以在同一组患者中评估其对其他疾病(动脉粥样硬化、癌症、前列腺肥大、骨质疏松、胰岛素抵抗、阿尔茨海默病和帕金森病、年龄相关性黄斑变性)的效果​​。如果群体规模较大,那么抗衰老效果可能会在几年内得到验证。令人惊讶的是,临床和临床前数据的回顾性分析揭示了四种潜在的抗衰老方式。
Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.
DOI: 10.1073/pnas.0403493101
发表时间: 2004-08-31
影响因子: 11.1
作者:
Bauer, JH;Goupil, S;Helfand, SL
通讯作者: Helfand, SL
DOI: 10.1681/asn.2004030180
发表时间: 2005-07-01
影响因子: 13.6
作者:
Bonegio, RGB;Fuhro, R;Lieberthal, W
通讯作者: Lieberthal, W
DOI: 10.1007/s10517-005-0389-9
发表时间: 2005-06-01
影响因子: 0.7
作者:
Anisimov, VN;Egormin, PA;Semenchenko, AV
通讯作者: Semenchenko, AV
DOI: 10.1073/pnas.0308291101
发表时间: 2004-04-27
影响因子: 11.1
作者:
Fontana, L;Meyer, TE;Holloszy, JO
通讯作者: Holloszy, JO
DOI: 10.1038/nature05354
发表时间: 2006-11-16
期刊: NATURE
影响因子: 64.8
作者:
Baur, Joseph A.;Pearson, Kevin J.;Sinclair, David A.
通讯作者: Sinclair, David A.